Advancing the Next Generation of Precision Kidney Disease Therapies from Discovery to Patients
With rare kidney drug development entering a new phase of clinical, genetic, and regulatory momentum, the 6th Rare & Genetic Kidney Disease Drug Development Summit will provide an essential platform for discovery, translational, clinical, regulatory strategy, and patient engagement biopharma experts from across the rare and genetic kidney disease space. This year's meeting will spotlight the strategies, data, and translational insights shaping the next generation of renal therapeutics.
Expect deep dives into:
- Renal disease biology, biomarker and surrogate endpoint development, and genetic screening
- Clinical trial design, patient recruitment, and real-world data integration
- Candid discussions on the practical decisions shaping rare and inherited kidney disease programs
Designed to enable industry-led connections with a room full of experts, join your community to benchmark your approach, uncover where the field is heading, forge valuable partnerships, and gain the insights needed to accelerate meaningful therapies for patients with rare kidney diseases.
Unmissable Event Highlights
Innovating Trial Design for Rare Kidney Disease Programs
Hear from Travere Therapeutics, Vera Therapeutics, and KidneyFuture on how real-world data, external control arms, and adaptive platform designs can reduce recruitment burden and improve rare kidney trial feasibility.
Advancing Endpoint Validation to Unlock Faster Clinical Proof-of-Concept
Join Alexion Pharmaceuticals, Bayer, and the University of Michigan to explore how proteinuria, tissue profiling, and advanced imaging can support earlier proof-of-concept and strengthen regulatory alignment.
Building Collaborative Ecosystems to Accelerate Innovation and Trial Success
Gain perspectives from Boehringer Ingelheim, NephroDI, and the University of Michigan on how cross-sector partnerships can improve data sharing, trial design, and scalable research platforms.
Embedding the Patient Voice to Improve Trial Design and Adoption
Hear from Boehringer Ingelheim, Vertex Pharmaceuticals, Amicus Therapeutics, and Maze Therapeutics on how patient input is shaping trial design, endpoint selection, and treatment delivery.
2026 Rare Kidney Disease Treatment Progress So Far...
January 2026
Once investigated for its use in COVID-19, Boehringer Ingelheim’s TRPC6 inhibitor apecotrep (BI 764198) results in reduced proteinuria in patients with focal segmental glomerulosclerosis (FSGS).
February 2026
Roche’s phase 2 MAJESTY trial of anti-CD20 antibody Gazyva met its primary endpoint, raising the prospect of a first approved therapy for primary membranous nephropathy (pMN).
March 2026
Vertex Pharmaceutical's kidney disease drug (povetacicept) hits mark in Phase 3 trial in IgA nephropathy, resulting in roughly 50% reduction of proteinuria versus placebo – positioning the drug as having a “best-in-class potential”.
April 2026
Travere Therapeutics’ Filspari becomes the first FDA-approved treatment for rare kidney disease, focal segmental glomerulosclerosis (FSGS), marking a historical milestone for patients living with this devastating condition.
June 2026
Everest Medicines signs $1B deal with Travere Therapeutics for BTK inhibitor aimed at rare kidney diseases.
Explore the Full Event Guide
- See how companies are tackling challenges from preclinical target validation through clinical development, payer engagement, and asset evaluation
- Preview strategies across 5+ rare kidney disease indications
- Insights from the companies and experts advancing renal pipelines
- Learn how teams are addressing surrogate endpoints, clinical trial design, and patient recruitment
- Share key insights with internal stakeholders to align your team
Attending Companies Include
What Your Peers Had to Say:
This meeting provides a unique forum for clinicians, drug developers, academics, regulators, patient representatives, and other stakeholders to come together, exchange innovative ideas, and help transform the lives of patients affected by rare and genetic renal diseases.
Executive Director, Global Clinical Lead Cardiovascular & Renal
There is such a sense of camaraderie at the Rare & Genetic Kidney Disease Summit. All stakeholders understand the significant unmet need and are working collaboratively to advance the field. This meeting is a great way to quickly build knowledge, insights, and connections.
Executive Director
Explore the Agenda
Hear the latest breakthroughs in biomarker validation, surrogate endpoints, and clinical trial design through a packed agenda featuring 3 expert panel discussions, 3 pre-conference workshops, 2 interactive roundtables, and 12+ data-driven case study presentations.
Partner With Us
Position yourself alongside leading solution providers supporting rare and genetic kidney disease pipelines. Whether your expertise lies in preclinical or clinical research, novel biomarkers for diagnosis, stratification or monitoring, imaging, or genetic testing, ensure your brand is at the center of key conversations around clinical development, endpoint validation, and trial execution
Join Biopharma Experts
Engage with a uniquely focused audience of rare and genetic kidney disease decision-makers and be part of high-value conversations with like-minded attendees across all stages of drug development, building critical connections through dedicated networking opportunities